Multicenter randomized trial shows aragonite-based scaffold improves outcomes in osteoarthritis, indicating its potential benefit.
The results confirmed that the aragonite-based scaffold is both safe and superior to SSOC in improving clinical outcomes at up to 5 years' evaluation, as well as in patients with mild to moderate OA.
No takes yet. Share an insight, caveat, or question.
Altschuler et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: